# reload+after+2024-01-20 15:43:21.476866
address1§32 Wiggins Avenue
city§Bedford
state§MA
zip§01730
country§United States
phone§781 457 9000
fax§781 305 9720
website§https://www.anikatherapeutics.com
industry§Medical Instruments & Supplies
sector§Healthcare
longBusinessSummary§Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
fullTimeEmployees§345
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Cheryl Renee Blanchard Ph.D.', 'age': 59, 'title': 'President, CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1310381, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael L. Levitz', 'age': 49, 'title': 'Executive VP, CFO & Treasurer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 710600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Colleran J.D.', 'age': 51, 'title': 'Executive VP, General Counsel & Corporate Secretary', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 664541, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anne  Nunes', 'age': 54, 'title': 'Senior VP & COO', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ian W. McLeod', 'title': 'VP & Chief Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Namaroff', 'age': 60, 'title': 'Executive Director of Investor Relations & Corporate Communications', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Chase', 'title': 'Senior Vice President of International Sales & Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ben  Joseph', 'title': 'Vice President of Commercial & Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lisa  Funiciello', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§2
compensationRisk§4
shareHolderRightsRisk§5
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.763
priceToSalesTrailing12Months§1.9785607
currency§USD
dateShortInterest§1702598400
forwardEps§-0.31
pegRatio§-1.82
exchange§NMS
quoteType§EQUITY
shortName§Anika Therapeutics Inc.
longName§Anika Therapeutics, Inc.
firstTradeDateEpochUtc§736435800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ef258dda-d89e-3407-b824-c5d0079911f4
gmtOffSetMilliseconds§-18000000
targetHighPrice§32.0
targetLowPrice§22.0
targetMeanPrice§27.67
targetMedianPrice§29.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§3.753
grossMargins§0.63736
ebitdaMargins§-0.07971
trailingPegRatio§None
